Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 24:16:1494411.
doi: 10.3389/fendo.2025.1494411. eCollection 2025.

Interaction of GPER-1 with the endocrine signaling axis in breast cancer

Affiliations
Review

Interaction of GPER-1 with the endocrine signaling axis in breast cancer

Luis Molina Calistro et al. Front Endocrinol (Lausanne). .

Abstract

G Protein-Coupled Estrogen Receptor 1 (GPER-1) is a membrane estrogen receptor that has emerged as a key player in breast cancer development and progression. In addition to its direct influence on estrogen signaling, a crucial interaction between GPER-1 and the hypothalamic-pituitary-gonadal (HPG) axis has been evidenced. The novel and complex relationship between GPER-1 and HPG implies a hormonal regulation with important homeostatic effects on general organ development and reproductive tissues, but also on the pathophysiology of cancer, especially breast cancer. Recent research points to a great versatility of GPER-1, interacting with classical estrogen receptors and with signaling pathways related to inflammation. Importantly, through its activation by environmental and synthetic estrogens, GPER-1 is associated with hormone therapy resistance in breast cancer. These findings open new perspectives in the understanding of breast tumor development and raise the possibility of future applications in the design of more personalized and effective therapeutic approaches.

Keywords: GPER-1; breast cancer; endocrine resistance; estrogen; hypothalamic-pituitary-gonadal axis; personalized medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Overexpression of GPER-1 during Epithelial-Mesenchymal Transition in Breast Cancer. Prolonged exposure to noxious stimuli, such as xenoestrogens or other estrogenic molecules, creates a favorable tumor environment for epithelial-mesenchymal transition in breast cancer cells. This is characterized by increased expression of GPER-1 in the tumor cell, leading to increased activity of signaling pathways dependent on this receptor.
Figure 2
Figure 2
GPER-1 plays a crucial role in the physiological regulation of the HPG axis. GPER-1 is involved in the intricate regulatory network of the hypothalamic-pituitary-gonadal (HPG) axis. The ubiquity of this receptor, both in the central nervous system and in peripheral tissues, determines an integrative role of neuroendocrine and environmental signals. In the hypothalamus and pituitary, GPER-1 modulates the synthesis and pulsatile release of gonadotropins, hormones essential for follicular development, ovulation and spermatogenesis. In the ovaries, GPER-1 mediates the effects of estradiol on cell proliferation, apoptosis and steroid synthesis, thus influencing ovarian function and fertility. The mammary gland, another target tissue of GPER-1, undergoes morphological and functional changes in response to hormonal fluctuations. Disruption of GPER-1 signaling by exposure to estrogenic chemicals or physiological alterations such as menopause can trigger a cascade of events leading to reproductive, metabolic and carcinogenic disorders.

Similar articles

Cited by

References

    1. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. (2014) 5:412–24. doi: 10.5306/wjco.v5.i3.412 - DOI - PMC - PubMed
    1. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers. (2021) 13:4287. doi: 10.3390/cancers13174287 - DOI - PMC - PubMed
    1. Fox S, Speirs V, Shaaban AM. Male breast cancer: An update. Virchows Archiv: Int J Pathol. (2022) 480:85–93. doi: 10.1007/s00428-021-03190-7 - DOI - PubMed
    1. Mueller C, Haymond A, Davis JB, Williams A, Espina V. Protein biomarkers for subtyping breast cancer and implications for future research. Expert Rev Proteomics. (2018) 15:131–52. doi: 10.1080/14789450.2018.1421071 - DOI - PMC - PubMed
    1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. . Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast (Edinburgh Scotland). (2022) 66:15–23. doi: 10.1016/j.breast.2022.08.010 - DOI - PMC - PubMed

LinkOut - more resources